NCT02773290已完成2 期
Phase 2/3 Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia Refractory to or Ineligible for Immunosuppressive Therapy
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 46
- 试验地点
- 3
- 主要终点
- Proportion of subjects achieving a hematological response (any of the platelet response, erythroid response, and neutrophil response) at Week 27
研究概览
简要总结
The objective of this study is to evaluate the efficacy of romiplostim administered once weekly to Aplastic Anemia (AA) patients with thrombocytopenia refractory to or ineligible for immunosuppressive therapy in Japan and Korea.
Safety and pharmacokinetics of romiplostim after repeated administration will also be assessed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of Aplastic Anemia (AA) confirmed by peripheral blood and bone-marrow examinations, etc.
- •Refractory to at least one course of immunosuppressive therapy including horse or rabbit anti-human thymocyte immunoglobulin (ATG); or ineligible for ATG treatment and refractory to cyclosporin (CyA)
- •Thrombocytopenia defined as a platelet count of ≤ 30 × 10^9/L
- •Preserving main organ function as a result of screening as follows;
- •Total bilirubin: < 1.5 times the upper limit of the laboratory normal range
- •Alanine aminotransferase: < 3.0 times the upper limit of the laboratory normal range
- •Aspartate aminotransferase: < 3.0 times the upper limit of the laboratory normal range
- •Creatinine value: ≤ 2.0 mg/dL
- •An Eastern Cooperative Oncology Group performance status score of 0 to 2 at screening
- •≥ 20 years of age at the time of obtaining informed consent
- •Patients who have provided written informed consent of their free will to participate in this study
排除标准
- •Concurrent active infection not adequately responding to appropriate therapy
- •Bone marrow reticulin grade of ≥ 2 based on the grading scale for reticulin indicated in Bone Marrow Pathology (2nd edition)
- •Proportion of blasts in bone marrow > 2%
- •Previous or concurrent active malignancies, other than localized tumors diagnosed more than one year previously and treated surgically with curative intent (basal cell carcinoma; or surgically resected in situ carcinoma of the cervix with an apparent success of ≥ 12 months prior to enrollment; as well as other cancers which have not been treated and remained disease-free for at least 5 years before enrollment are eligible)
- •Clinically significant cardiac disease (class III or IV of the New York Heart Association classification; unstable angina pectoris; myocardial infarction within 6 months before enrollment; cardiac disease accompanied by angioplasty or stenting within 6 months before enrollment; or clinically significant cardiac arrhythmias) or uncontrollable hypertension
- •Arterial or venous thrombosis within one year before enrollment
- •Positive for anti-human immunodeficiency virus antibodies, hepatitis B surface antigen, or hepatitis C virus-RNA at screening
- •Thrombocytopenia due to any other cause (e.g., myelodysplastic syndrome, idiopathic thrombocytopenic purpura, or liver cirrhosis)
- •Patients with acute myeloblastic leukemia or chronic myelomonocytic leukemia
- •Concurrent occurrence of hemolytic predominant paroxysmal nocturnal hemoglobinuria (Hemolytic predominant is defined as lactate dehydrogenase > 1.5 times the upper limit of the laboratory normal range)
- •Uncontrolled diabetes mellitus
- •Receiving other investigational products within 16 weeks before romiplostim treatment initiation
- •Receiving any agent to treat AA, including the following agents before romiplostim treatment initiation;
- •ATG treatment within 6 months before romiplostim treatment initiation
- •CyA or anabolic steroid treatment within 6 weeks before romiplostim treatment initiation:
- •However, the patients who are treated with a CyA or anabolic steroid for at least 6 months before romiplostim treatment initiation may be enrolled if their blood cell count are stable at screening, and their dosage and administration will be kept for 6 weeks before romiplostim treatment initiation and during romiplostim dosing period.
- •A history of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor, recombinant human thrombopoietin (TPO), romiplostim, or other TPO-receptor agonists
- •Having a plan to undergo hematopoietic stem cell transplantation within 1 year
- •Having hypersensitivity to any recombinant protein E. coli derivative protein
- •Lactating or pregnant women or women of child-bearing potential who have no intention of using oral contraceptives or birth control
- •Having abnormalities by the cytogenetic test in bone marrow cells
- •Patients who are considered to be ineligible for the study by the investigator or subinvestigator for reasons other than above
结局指标
主要结局
Proportion of subjects achieving a hematological response (any of the platelet response, erythroid response, and neutrophil response) at Week 27
时间窗: At 27 weeks after dosing
次要结局
- Proportion of subjects with a hematological response at the end-of- treatment examination(Up to 52 weeks after dosing)
- Time from the first romiplostim administration to hematological response(Up to 52 weeks after dosing)
- In subjects receiving platelet transfusion as a pretreatment within 8 weeks prior to the first romiplostim administration; proportion of subjects with transfusion independence or decreased platelet transfusion requirement(Up to 52 weeks after dosing)
- Proportion of subjects achieving platelet response, erythroid response, or neutrophil response at each of Week 27 and end of treatment.(At 27 weeks and 52 weeks after dosing)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric SubjectsThrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)Idiopathic Thrombocytopenic PurpuraNCT00515203Amgen22
已完成
2 期
Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating AgentsMDSMyelodysplastic SyndromesThrombocytopeniaNCT00321711Amgen69
Unknown
2 期
An Observational Study to Evaluate the Efficacy of Biweekly Romiplostim in Adult Patients With ITPImmune ThrombocytopeniaNCT02338414Samsung Medical Center20
已完成
1 期
Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)Thrombocytopenic PurpuraNCT00117143Amgen16
已完成
3 期
Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)Immune ThrombocytopeniaNCT02868099Kyowa Kirin China Pharmaceutical Co., Ltd.203